SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    H Honda, A Nagamachi, T Inaba, −7/7q− syndrome in myeloid-lineage hematopoietic malignancies: attempts to understand this complex disease entity, Oncogene, 2014,

    CrossRef

  2. 2
    John F. Seymour, John M. Bennett, Alan F. List, Ghulam J. Mufti, Steven D. Gore, Pierre Fenaux, Valeria Santini, Joel Hetzer, Stephen Songer, Barry S. Skikne, Charles L. Beach, Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes, British Journal of Haematology, 2014, 165, 1
  3. 3
    Daiane Corrêa de Souza, Cecília de Souza Fernandez, Adriana Camargo, Alexandre Gustavo Apa, Elaine Sobral da Costa, Luis Fernando Bouzas, Eliana Abdelhay, Teresa de Souza Fernandez, Cytogenetic as an Important Tool for Diagnosis and Prognosis for Patients with Hypocellular Primary Myelodysplastic Syndrome, BioMed Research International, 2014, 2014, 1

    CrossRef

  4. 4
    Guillermo Garcia-Manero, Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management, American Journal of Hematology, 2014, 89, 1
  5. 5
    Fabiola Fernandes Heredia, Juliana Cordeiro de Sousa, Howard Lopes Ribeiro Junior, Alex Fiorini Carvalho, Silvia Maria Meira Magalhaes, Ronald Feitosa Pinheiro, Proteins related to the spindle and checkpoint mitotic emphasize the different pathogenesis of hypoplastic MDS, Leukemia Research, 2014, 38, 2, 218

    CrossRef

  6. 6
    Peter Hokland, Finbarr Cotter, Publishing data from failed cytogenetic assays– what can we learn?, British Journal of Haematology, 2014, 164, 2
  7. 7
    Emanuela Boveri, Giorgio Croci, Umberto Gianelli, Marcello Gambacorta, Giuseppe Isimbaldi, Alessia Moro, Andrea Gianatti, Marco Ungari, Enrica Morra, Histopathological and immunohistochemical evaluation of bone marrow biopsy in myelodysplastic syndromes, International Journal of Hematologic Oncology, 2013, 2, 3, 219

    CrossRef

  8. 8
    Y. Saunthararajah, Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes, Hematology, 2013, 2013, 1, 511

    CrossRef

  9. 9
    Drorit Merkel, Kalman Filanovsky, Anat Gafter-Gvili, Liat Vidal, Ariel Aviv, Moshe E. Gatt, Itay Silbershatz, Yair Herishanu, Ariela Arad, Tamar Tadmor, Najib Dally, Anatoly Nemets, Ory Rouvio, Aharon Ronson, Katrin Herzog-Tzarfati, Luiza Akria, Andrei Braester, Ilana Hellmann, Shay Yeganeh, Arnon Nagler, Ronit Leiba, Moshe Mittelman, Yishai Ofran, Predicting infections in high-risk patients with myelodysplastic syndrome/acute myeloid leukemia treated with azacitidine: Aretrospective multicenter study, American Journal of Hematology, 2013, 88, 2
  10. 10
    H. Signorelli, DO, Predicting Survival of Patients With Hypocellular Myelodysplastic Syndrome: Development of a Disease-Specific Prognostic Score System, Yearbook of Pathology and Laboratory Medicine, 2013, 2013, 372

    CrossRef

  11. 11
    A. M. Mohamedali, H. Alkhatabi, A. Kulasekararaj, S. Shinde, S. Mian, F. Malik, A. E. Smith, J. Gaken, G. J. Mufti, Utility of peripheral blood for cytogenetic and mutation analysis in myelodysplastic syndrome, Blood, 2013, 122, 4, 567

    CrossRef

  12. 12
    Paolo Bernasconi, Catherine Klersy, Marina Boni, Paola Maria Cavigliano, Irene Dambruoso, Rita Zappatore, Validation of the new comprehensive cytogenetic scoring system (NCCSS) on 630 consecutive de novo MDS patients from a single institution, American Journal of Hematology, 2013, 88, 2
  13. You have free access to this content13
    Guillermo Garcia-Manero, Myelodysplastic syndromes: 2012 update on diagnosis, risk-stratification, and management, American Journal of Hematology, 2012, 87, 7
  14. 14
    Ulrich Germing, Andrea Kündgen, Prognostic scoring systems in MDS, Leukemia Research, 2012, 36, 12, 1463

    CrossRef